RRN3

Across TCGA pan-cancer cohorts, RRN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RRN3 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RRN3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RRN3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where RRN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.837	1.000	.005	14	view →
CCRCC	DFS	Median	II,III,IV	0.495	0.893	.005	14	view →
LUAD	DFS	Quartile	III,IV	0.854	0.358	.008	12	view →
GBM	DFS	Tertile	All	0.514	0.260	.015	5	view →
HNSC	OS	Median	III,IV	0.916	0.782	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RRN3–PDAC (OS)

Open the PDAC breakdown →